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Abstract
Background: Identification of predictive and prognostic biomarkers for patients with disease and undergoing
different therapeutic options is a very active area of investigation. Many of these studies seek biomarkers among
circulating proteins accessed in blood. Many levels of standardization in materials and procedures have been
identified which can impact the resulting data.
Methods: Here, we have observed unexpected variability in levels of commonly tested analytes in serum which
were processed and stored under standardized conditions. We have identified apparent changes in cytokine,
chemokine and growth factor levels detected by multiplex Luminex assay in melanoma patient and healthy donor
serum samples, over storage time at -80°C. Controls included Luminex kit standards, multiplexed cytokine standards
and WHO cytokine controls. Data were analyzed by Wilcoxon rank-sum testing and Spearman’s test for correlations.
Results: The interpretation of these changes is confounded by lot-to-lot kit standard curve reagent changes made
by a single manufacturer of Luminex kits.
Conclusions: This study identifies previously unknown sources of variation in a commonly used biomarker assay,
and suggests additional levels of controls needed for identification of true changes in circulating protein levels.
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Background
To improve the clinical efficacy of immunotherapies and
our ability to stratify patients rationally for therapeutic
intervention, biomarkers are critical to progress. The
FDA’s Critical Path prioritizes development of biomar-
kers, including a focus on aspects of: Biospecimens,
Analytical Performance, Standardization and Harmoni-
zation and Bioinformatics. Accurate biomarkers offer
the prospect for earlier diagnosis, improved precision of
application of expensive and toxic therapies on the opti-
mal patient populations, monitoring disease progression
and therapeutic benefits as well as accelerating drug
development and discovery. Guidelines for incorporation
of biomarker studies in early clinical trials of novel
agents have been published [1].
There is a critical need for development and validation
of biomarkers to identify patients who can benefit from
a particular form of immunotherapy. Only a fraction of
patients benefit from IFN-a treatment [2], only a frac-
tion of patients can achieve durable regressions in
response to antigen vaccination [3], or antibody thera-
pies, and we do not yet know the mechanisms responsi-
ble for therapeutic benefit. Despite substantial efforts
from many groups, we do not know which parameters
of immune response (and which assays used to assess
these parameters) yield optimal results for efficacy ana-
lysis [4-7]. A major reason for this has been that objec-
tive clinical response rates are often below 10%,
confounding the measurement of significant correlations
between biomarkers and clinical responses in studies of
modest size. Another important issue is that assay
results may depend on biological specimen handling
before assessment, and on methodological differences in
complex, high throughput assays.
A number of studies in melanoma have identified can-
didate biomarkers of response to therapy. These range
from circulating cytokines and growth factors [8,9], gene
expression profiles in tumors [10], circulating tumor
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specific T cell IFN-g production [13] to molecular sig-
naling pathways in tumors [14] and the nature of tumor
infiltrating cells [15]. The vast majority of candidate bio-
markers have not yet achieved routine clinical use due
to lack of reproducibility, need for new technology and
equipment, need for high quality tumor samples or high
cost. The relative ease of collecting, processing, storing
and shipping blood has made it a common resource for
biomarker testing.
Several reports have identified phenotypic and func-
tional changes in blood cells and serum components
when the blood is held for hours or days and at differ-
ent temperatures before processing [16-18]. These time-
dependent and temperature-dependent effects should be
controlled for to the extent possible before blood pro-
cessing. Standardized processing procedures by trained
and competency-tested personnel can also improve
i m m u n o l o g i ca s s a yd a t ac o n s i stency [19]. In addition,
use of freezers for sample storage that are monitored for
temperature stability and that have 24 hours-a-day
alarm response eliminates concerns that samples might
undergo freeze-thaw cycles or be otherwise compro-
mised by temperature changes during storage. Many of
these central laboratory procedures for processing, sto-
rage and equipment maintenance are mandated by
accreditation groups such as CLIA and FACT, and are
described in resources from CLSI [20-22].
During an investigation of biomarkers of prolonged
survival after IFN-a treatment in banked melanoma
patient serum samples, we discovered a number of both
technical and biostatistical analysis issues [23]. Our pre-
liminary results identified a large number of serum cyto-
kines that appeared to correlate significantly with
survival. However, further dissection of the data revealed
a number of technical issues that made interpretation of
the data impossible.
H e r e ,w eh a v ep e r f o r m e dat i m ec o u r s ea n a l y s i so f
cytokines, chemokines and growth factors measured in
the banked serum of healthy donors and melanoma
patients stored for various intervals, and analyzed by
multiplex Luminex assay. We find that a number of
these analytes appear to be unstable during storage. We
have also tested several aspects of the Luminex assay
performance and identified a number of concerns with
these multiplexed assays. Biostatistical tests indicate that
despite several layers of procedural standardization and
levels of controls, reliable multiplexed cytokine and che-
mokine determinations may be compromised by length
of time in storage and/or by the changes regularly made
by assay kit manufacturers to different lots and the ana-
lyte standards included. These results raise concerns
about serum biomarker studies and suggest that addi-
tional controls may be required to confidently compare
levels over time and between lots of reagents from the
same manufacturer.
Methods
Study subjects
All serum samples were obtained after written informed
consent, and under IRB approved protocols of investiga-
tion at the University of Pittsburgh. The samples
received in 2005 were obtained from 23 patients at two
clinical sites (Pennsylvania and Indiana). The UPCI #96-
099 banking protocol was utilized for the five 2010 mel-
anoma patient sera tested. The UPCI #04-001 healthy
donor blood collection protocol was used for the blood
obtained from 10 healthy donors in 2010.
Blood processing and banking
For serum collection, red top vaccutainer tubes (no
anticoagulant) provided by our laboratory (Becton Dick-
inson #6430) in kits were used. Upon arrival in the lab,
the samples are checked for proper identification, given
accession numbers, and either processed immediately or
(if received after 4 pm) put in the refrigerator (at 4°C)
for processing the next morning. All samples were pro-
cessed within 24 hours, including those drawn at exter-
nal sites and shipped at ambient temperature overnight
in insulated shipping containers. All processing was per-
formed by technologists who received the same training,
and the laboratory SOP #0108 was followed. Technolo-
gists also undergo annual competency training. Samples
were centrifuged for 10 min at 2, 500 rpm in a refriger-
ated centrifuge at 4°C, then the serum was aliquoted
into polypropylene freezer vials at 1.1 mL per vial and
immediately placed in a -80°C freezer. All samples were
stored in a monitored freezer until testing, freezer tem-
peratures did not fluctuate above -55°C (during brief
periods of high use). Samples were thawed before testing
and repeated testing was performed on separate aliquots
to eliminate variability from freeze-thaw cycles. The
laboratory is certified under the Pennsylvania Depart-
ment of Health, College of American Pathologists (CAP)
and Clinical Laboratory Improvement Amendments
(CLIA for Histocompatibility and General Immunology).
The laboratory is registered with the FDA, and main-
tains a facilities master file (BB-MF-12244). The
exploratory Luminex assay reported here is not used for
clinical decision making, and is not a CLIA-certified
assay.
Luminex assay and controls
The Luminex kits were obtained from the same manu-
facturer, which changed ownership during the period of
the study (BioSource, Invitrogen, Life Technologies).
Assays were performed only on serum samples that had
been stored at -80°C. Serum samples were thawed in a
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hours total time) or at room temperature the day of the
assay (patient samples), clarified in a microfuge for 10
min at 1, 000 g, then diluted with the assay diluent pro-
vided per assay manufacturer’s instructions. Healthy
donor and control samples were run in duplicate, but
l a r g en u m b e r so fp a t i e n ts e r aw e r er u ni ns i n g l e t s .T h e
same trained technologist performed all of the assays
reported herein, according to the same laboratory SOP
#0037). The software used for all assays was the BioPlex
System BioPlex Manager 4.0, which uses 5-parameter
logistic regression. Each sample acquired ≥ 100 bead
events, per manufacturers’ instructions. Analytical sensi-
tivity was calculated based on two standard deviations
from the background MFI of the standard curve. There
were no changes in the antibodies used for the analytes
of interest reported here, and the standards were bench-
marked in the same way over the time period tested
here. R&D QC controls (R&D Systems QC02) are
reconstituted with assay diluent from the Hu Extracellu-
lar buffer kit LHB0001 (BioSource). Each lot provides
expected values for several commonly tested cytokines
(as measured by R&D Systems ELISA assays). Additional
kit details are presented in Additional File 1, Table S1.
To address potential inter-analysis variability, 770 data
points from 2005 and 430 data points from 2010 were
re-analyzed at the same time (2011) with version 6.0
software, on the original machine. There were 0/1, 200
changes in the resulting absolute values obtained.
WHO cytokine standards
WHO cytokine standards were resuspended as follows:
117187 GM-CSF WHO 88/646 10, 000 IU: contents of
the ampoule were dissolved with 0.5 mL sterile distilled
water and brought up to 1 mL with PBS. Further 1:10
dilution was performed with AIM V (Invitrogen) med-
ium. 117173 IL-4 WHO 88/656 0.1 μg = 1, 000 arbitrary
units per ampoule: contents of the ampule were resus-
pended with PBS/1% BSA, and the 1:10 dilution was
performed with AIM V. 117184 IL-10 WHO 92/516 1
μg = 5, 000 RU per ampoule: contents of the ampoule
were dissolved with 0.5 mL sterile distilled water and
then brought up to 1 mL with PBS. Further 1:10 dilu-
tion was performed with AIM V. 117177 IL-8 WHO 89/
520 1 μg = 1, 000 RU per ampoule = 1, 000, 000 pg/mL:
contents of the ampoule were resuspended with PBS/1%
BSA and the 1:10 dilution was performed with AIM V.
To assay the WHO standards, each was diluted 1:10 (20
μL WHO standard dilution (above) + 180 μL assay dilu-
ent) and 1:50 (10 μLW H O+4 9 0μL assay diluent).
The dilutions were treated as samples in the assay, such
that the final dilutions were 1:20 and 1:100, relative to
the Luminex kit standard curve (the assayed well con-
tains 50 μL of the dilution + 50 μL of assay diluent).
Biostatistical Methods
Analyte concentrations were compared at two time
points with a one-sample Wilcoxon rank-sum test on
the ratio of the two concentrations. Correlation was
assessed with Spearman’st e s t .A l lp - v a l u e sa r et w o -
sided. Assay results below the lower limit of detection
or above the upper limit of quantitation were not used
in the analysis.
Results and Discussion
During the analysis of a retrospective biomarker study
conducted with a set of banked sera from melanoma
patients [23], we discovered a potential correlation
between the levels of analytes measured by Luminex
and the time that the sera were stored at -80°C. There-
fore, we examined several aspects of serum storage and
the Luminex assay.
Repeat testing in 2010 of sera stored in 2005
Our first sample set consisted of 23 melanoma patient
sera (the “old patients”) who had a blood sample drawn
in 2005, and had a Luminex assay performed on serum
samples, on either 10/31/2005, 11/01/2005 or 2/17/2006;
we refer to these as the “early” assays. To determine any
changes over storage time, we thawed aliquots (not pre-
viously thawed) and tested a subset of the analytes origin-
ally tested, again by Luminex (Table 1). Unexpectedly, we
identified a number of apparent changes in analyte levels.
We repeated these measurements up to three times
(depending on the number of previously untouched ali-
quots remaining) for these 23 samples: (2/02/10, 5/13/
2010 and 8/11/2010)–the “late” assays. Seven of the 10
analytes we examined had highly significant changes dur-
ing the approximately 5 years of storage at -80°C.
There were different patterns seen for different groups
of analytes, some of which were relatively stable over
time (IL-4, change over time: p = 0.28) while others were
found to change (IL-10, p = 0.093; GM-CSF, p = 0.11).
Levels of some of the analytes decreased over the storage
time (IL-6, p = 0.00021; decreasing in 21/23 samples;
TNFa, p = 0.0078, decreasing in 20/23). Surprisingly, the
IL-8 levels were significantly increased from the initial
test to the subsequent tests 5 years later (IL-8, p =
0.000030, approximately 5-fold increased in 23/23 patient
samples). MCP-1 levels also increased in a majority of
samples (MCP-1, p = 0.00012) (Table 1/Figure 1). Each
p-value was computed with a one-sample Wilcoxon test
on the ratio of the 5/13/2010 assay result (for which we
had the most data) to the result of the early assay.
Healthy donor and melanoma patient serum time course
in 2010
To determine whether we could detect similar changes
over a period of months, we drew blood from 10 healthy
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Sample Date
Drawn
Draw
Date
Assay
Date
IL-4
pg/mL
IL-6
pg/mL
IL-8
pg/mL
IL-10
pg/mL
TNF-a
pg/mL
IFN-g
pg/mL
GM-CSF
pg/mL
IP-10
pg/mL
MIG
pg/mL
MCP-1
pg/mL
patient 1 6/2/2005 6/1/2005 10/31/2005 < 5 217 64 < 10 38 29 < 15 1339 62 10145
8/11/2010 25 106 353 6 < 10 28 < 15 1214 48 > 7200
8/11/2010 16 98 370 6 < 10 29 < 15 1195 42 > 7200
patient 2 6/2/2005 6/1/2005 10/31/2005 < 5 41 24 < 10 19 23 < 15 > 2800 130 2725
8/11/2010 13 20 132 7 < 10 24 < 15 > 9600 164 3149
8/11/2010 13 22 144 7 < 10 26 < 15 > 9600 162 2989
patient 3 6/2/2005 6/1/2005 10/31/2005 < 5 13 23 < 10 7 < 14 < 15 55 62 384
8/11/2010 5 5 125 5 < 10 < 5 < 15 83 90 419
8/11/2010 7 6 151 5 < 10 < 5 < 15 83 98 455
patient 4 7/30/2005 7/30/2005 11/1/2005 32 49 17 17 83 95 173 64 241 394
2/2/2010 47 17 75 20 21 63 132 87 209 633
5/13/2010 42 14 73 20 20 51 124 84 153 554
5/13/2010 42 15 69 22 21 62 133 84 154 518
8/11/2010 55 21 89 27 28 118 89 90 213 140
8/11/2010 47 23 87 33 32 144 105 90 209 128
patient 5 8/9/2005 8/9/2005 11/1/2005 12 2199 266 43 100 178 < 15 > 2800 407 > 17800
2/2/2010 6 1105 1469 < 14 17 159 37 2178 374 11991
5/13/2010 13 949 1494 < 14 16 140 36 2476 313 10275
5/13/2010 12 971 1428 < 14 13 121 24 2233 300 9045
patient 6 8/9/2005 8/9/2005 11/1/2005 14 592 171 28 52 229 < 15 > 2800 2586 10705
2/2/2010 10 350 1016 < 14 < 10 198 37 2176 2039 11703
5/13/2010 13 275 971 < 14 < 10 155 18 > 2980 2276 9492
5/13/2010 < 5 270 968 < 14 < 10 160 11 > 2980 2294 10581
patient 7 8/15/2005 8/15/2005 11/1/2005 < 5 19 47 < 5 13 < 14 < 15 285 40 2565
5/13/2010 8 24 242 < 14 < 10 31 < 15 445 25 5453
5/13/2010 < 5 20 234 < 14 < 10 27 < 15 360 25 5088
patient 8 8/20/2005 8/20/2005 11/1/2005 36 48 17 17 80 111 197 27 182 379
2/2/2010 46 17 99 23 23 78 146 45 172 614
5/13/2010 48 16 87 26 25 84 175 40 128 550
5/13/2010 50 15 84 22 21 70 151 41 117 544
8/11/2010 33 15 89 23 21 103 85 47 136 119
8/11/2010 49 21 107 29 30 136 95 48 150 125
patient 9 9/15/2005 9/15/2005 11/1/2005 42 67 21 11 72 122 208 275 383 1119
5/13/2010 77 22 78 28 36 80 224 346 328 2162
5/13/2010 80 22 76 27 34 87 233 347 306 2270
patient 10 9/19/2005 9/19/2005 2/17/2006 < 5 19 45 < 5 13 < 7 < 15 183 42 1656
5/13/2010 8 24 287 < 14 < 10 26 < 15 350 21 5509
5/13/2010 8 22 290 < 14 < 10 29 < 15 347 17 5021
patient 11 9/16/2005 9/22/2005 11/1/2005 48 94 2675 24 142 135 201 902 419 10026
5/13/2010 85 37 12663 29 39 114 272 988 300 13807
5/13/2010 77 37 13690 27 34 114 266 1337 285 14377
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8/11/2010 93 41 14814 26 59 72 219 716 340 > 7200
8/11/2010 110 48 12823 30 58 80 238 793 364 > 7200
patient 12 9/28/2005 9/28/2005 2/17/2006 62 92 27 39 82 183 328 51 270 436
2/2/2010 46 22 92 36 20 118 222 88 200 909
5/13/2010 43 18 75 35 20 109 221 76 125 741
5/13/2010 34 18 88 35 22 124 208 78 165 755
patient 13 10/6/2005 10/5/2005 11/1/2005 28 67 51 8 80 77 131 877 326 6818
8/11/2010 83 42 342 29 55 64 225 725 332 > 7200
8/11/2010 116 44 335 33 72 79 228 802 356 7345
patient 14 10/7/2005 10/6/2005 11/1/2005 42 67 24 18 66 122 156 353 711 1266
8/11/2010 89 39 118 35 66 59 237 314 906 1088
8/11/2010 70 35 114 30 53 52 189 328 891 1057
patient 15 10/12/2005 — 2/17/2006 51 76 26 32 86 180 276 63 257 395
2/2/2010 38 21 113 48 23 146 255 107 245 801
5/13/2010 35 17 95 44 23 116 205 89 170 601
5/13/2010 28 15 100 42 20 107 224 82 168 576
patient 16 10/17/2005 — 2/17/2006 < 5 54 60 < 5 34 < 7 < 15 434 55 3950
5/13/2010 5 41 368 < 14 < 10 39 < 15 780 25 10159
5/13/2010 11 43 373 < 14 < 10 39 < 15 846 23 10552
8/11/2010 21 52 402 6 < 10 6 15 464 35 4616
8/11/2010 8 29 391 < 5 < 10 < 5 < 15 465 35 4777
patient 17 11/3/2005 11/3/2005 2/17/2006 23 52 11 < 5 49 75 111 155 283 686
5/13/2010 72 23 57 24 31 67 221 198 288 1734
5/13/2010 17 9 27 < 14 < 10 14 53 186 218 1706
8/11/2010 90 36 63 28 60 67 222 203 370 757
8/11/2010 85 30 60 24 52 56 213 202 325 705
patient 18 11/16/2005 – 2/17/2006 7 18 14 < 5 20 29 44 41 79 327
2/2/2010 16 15 74 < 14 < 10 34 51 59 93 807
5/13/2010 10 12 71 < 14 < 10 20 24 57 50 611
5/13/2010 8 10 72 < 14 < 10 24 30 52 48 617
patient 19 11/16/2005 — 2/17/2006 10 48 18 < 5 41 39 67 144 96 1143
2/2/2010 16 30 116 < 14 < 10 43 75 248 108 2812
5/13/2010 13 22 100 < 14 10 35 67 202 75 2101
5/13/2010 11 24 108 < 14 < 10 38 61 220 67 2304
patient 20 12/8/2005 12/8/2005 2/17/2006 27 31 10 < 5 62 73 149 35 162 452
2/2/2010 49 17 61 24 24 89 146 60 162 1422
5/13/2010 43 12 48 19 24 70 137 52 108 1114
5/13/2010 41 12 50 21 21 77 137 55 106 1234
patient 21 12/12/2005 12/9/2005 2/17/2006 < 5 24 41 < 5 16 < 7 < 15 537 35 1236
5/13/2010 8 22 235 < 14 < 10 29 < 15 682 25 3153
5/13/2010 10 23 233 < 14 < 10 27 < 15 789 25 3457
8/11/2010 14 29 235 11 < 10 7 < 15 518 34 1423
8/11/2010 13 25 238 11 < 10 6 < 15 546 39 1322
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Page 5 of 14donors (HD, Additional File 2, Table S2, Table 2 data)
and 5 melanoma patients ("new patients”) (Additional
File 3, Table S3, Table 3 data). HD samples were tested
initially 2 months after processing and freezing, and
t h e nt w i c em o r e ,a t5a n d8m o n t h so fs t o r a g eo nt h e
same dates as the old patient sample described above.
The melanoma patient samples were tested 2 days after
processing and cryopreservation, and again 3 months
later.
As expected, HD samples had low circulating levels of
many analytes tested. These HD control samples also
showed changes in analyte levels, even after short-term
storage. Again, some analytes were stable, others were
much less stable. IL-8 increased in 3/10 HD, at the 8
month timepoint (n.s.), but not by 5 months. IP-10 also
b e g a nt oi n c r e a s ei n5 / 1 0H Da t8m o n t h s( p=0 . 0 1 ) .
Several analytes decreased in the relatively short storage
time interval, including IFNg (p = 0.06 at 5 mo., p =
0.03 at 8 mo., decreasing in 6/10 HD), and MCP-1,
which showed the most dramatic decreases in 10/10
donors, by 8 mo. (p = 0.002). These changes, between
the first assay and the second and third assays (100 and
190 days apart), are shown graphically in Figure 2. The
melanoma patient samples did not show significant
changes within the short storage time, with the excep-
tion of MCP-1, which decreased in 5/5 samples within 3
months (p = 0.06). When the ratios of the concentra-
tions of the different analytes measured at different
Table 1 Old patient Serum Samples (Continued)
patient 22 1/26/2006 1/25/2006 2/17/2006 8 30 4 < 5 24 24 40 706 216 24
8/11/2010 47 22 44 17 45 37 196 332 283 888
8/11/2010 56 26 47 19 53 42 223 318 283 959
patient 23 1/26/2006 1/25/2006 2/17/2006 8 56 68 < 5 75 20 < 15 8705 266 75
8/11/2010 75 3953 534 19 56 50 202 650 339 > 7200
8/11/2010 76 4542 525 19 58 48 210 695 318 > 7200
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Figure 1 Representative cytokine and chemokine changes over time. Data are shown for old patients 13 through 23, for cytokines IL-8 and
IL-10, and chemokine MCP-1. On a log scale, changes detected between 2005-2006 and 2010 assays are shown.
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Sample Date
Drawn
Assay
Date
IL-4
pg/mL
IL-6
pg/mL
IL-8
pg/mL
IL-10
pg/mL
TNF-a
pg/mL
IFN-g
pg/mL
GM-CSF
pg/mL
IP-10
pg/mL
MIG
pg/mL
MCP-1
pg/mL
Healthy donor 1 12/14/2009 2/2/2010 57 43 25 21 16 44 90 28 143 324
2/2/2010 58 48 22 25 16 49 94 30 143 319
5/13/2010 50 39 19 22 13 31 87 25 103 263
5/13/2010 52 29 18 17 11 29 78 25 100 254
8/11/2010 36 42 11 25 < 10 20 40 31 71 30
8/11/2010 29 39 11 20 < 10 16 39 29 64 31
Healthy donor 2 12/16/2009 2/2/2010 57 61 44 41 20 160 179 31 96 632
2/2/2010 59 59 40 42 18 163 151 31 105 589
5/13/2010 44 48 29 31 15 109 129 28 70 529
5/13/2010 41 49 34 33 15 109 128 27 69 521
8/11/2010 82 80 63 37 42 100 84 40 151 160
8/11/2010 67 91 68 39 34 105 81 35 165 138
Healthy donor 3 12/17/2009 2/2/2010 17 < 8 18 < 14 < 10 < 12 < 15 23 20 977
2/2/2010 21 < 8 19 < 14 < 10 < 12 < 15 23 13 921
5/13/2010 22 < 8 21 < 14 < 10 < 12 < 15 22 < 12 803
5/13/2010 20 < 8 18 < 14 < 10 < 12 < 15 23 < 12 763
8/11/2010 24 < 3 18 < 5 < 10 < 5 < 15 19 11 241
8/11/2010 32 < 3 21 < 5 < 10 < 5 < 15 23 16 258
Healthy donor 4 12/18/2009 2/2/2010 111 29 88 51 50 189 253 39 196 577
2/2/2010 121 31 90 51 56 212 262 37 216 579
5/13/2010 81 20 66 38 39 147 211 30 128 468
5/13/2010 76 21 60 36 33 142 201 30 133 440
8/11/2010 232 48 160 65 90 137 173 49 277 171
8/11/2010 222 46 167 68 92 141 167 48 276 183
Healthy donor 5 12/21/2009 2/2/2010 12 9 33 < 14 < 10 18 33 20 32 194
2/2/2010 < 5 < 8 30 < 14 < 10 14 25 20 13 192
5/13/2010 5 < 8 34 < 14 < 10 14 < 15 19 < 12 177
5/13/2010 < 5 < 8 32 < 14 < 10 < 12 < 15 20 12 174
8/11/2010 7 7 26 8 < 10 > 5 < 15 25 20 16
8/11/2010 12 12 33 10 < 10 < 5 23 27 20 17
Healthy donor 6 12/21/2009 2/2/2010 19 8 24 < 14 < 10 < 12 37 22 50 496
2/2/2010 < 5 < 8 28 < 14 < 10 < 12 17 22 37 558
5/13/2010 19 < 8 15 < 14 < 10 < 12 18 19 40 434
5/13/2010 10 < 8 < 12 < 14 < 10 < 12 18 18 36 413
8/11/2010 12 12 47 12 14 7 21 27 48 111
8/11/2010 18 11 45 13 13 7 21 28 51 108
Healthy donor 7 12/22/2009 2/2/2010 16 < 8 38 < 14 < 10 35 56 19 66 1040
2/2/2010 17 9 40 < 14 10 35 62 19 66 1019
5/13/2010 19 < 8 35 < 14 < 10 40 51 17 50 843
5/13/2010 20 < 8 41 < 14 < 10 33 51 18 53 848
8/11/2010 13 6 28 28 < 10 19 37 21 24 245
8/11/2010 16 10 30 41 11 25 49 24 24 246
Healthy donor 8 12/23/2009 2/2/2010 54 15 39 29 17 82 135 40 188 926
2/2/2010 58 17 33 29 17 78 123 42 188 934
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concentration changes observed were not significantly
different between the serum sample data sets (old
patients, HD, new patients) (Table 1, Table 2, Table 3).
Cytokine Controls used in assays
We purchased our Luminex kits from a single source,
however, that source changed ownership between Oct.
‘05 and Aug. ‘10 (from Biosource to Invitrogen to Life
Table 2 Healthy Donor Sera Analysis (Continued)
5/13/2010 64 15 37 32 21 76 144 38 160 815
5/13/2010 65 15 35 33 20 72 129 36 160 742
8/11/2010 23 < 3 10 8 < 10 9 22 34 71 144
8/11/2010 32 6 14 14 < 10 21 36 34 96 130
Healthy donor 9 12/24/2009 2/2/2010 < 5 9 17 < 14 < 10 < 12 < 15 21 13 969
2/2/2010 < 5 8 15 < 14 < 10 < 12 < 15 20 20 928
5/13/2010 < 5 < 8 13 < 14 < 10 < 12 < 15 17 < 12 784
5/13/2010 < 5 < 8 14 < 14 < 10 < 12 < 15 19 < 12 813
8/11/2010 8 11 19 9 < 10 6 < 15 29 20 332
8/11/2010 7 10 17 8 < 10 < 5 < 15 26 20 331
Healthy donor 10 12/28/2009 2/2/2010 < 5 8 < 12 < 14 < 10 < 12 < 15 37 13 1034
2/2/2010 < 5 < 8 < 12 < 14 < 10 16 < 15 37 13 990
5/13/2010 < 5 < 8 < 12 < 14 < 10 < 12 < 15 34 < 12 845
5/13/2010 < 5 < 8 < 12 < 14 < 10 < 12 < 15 36 < 12 802
8/11/2010 < 5 4 < 3 < 5 < 10 < 5 < 15 57 6 374
8/11/2010 5 5 < 3 < 5 < 10 8 < 15 59 11 385
Table 3 New Melanoma Patient Sera Analysis
Sample Draw
Date
Assay
Date
IL-4
pg/mL
IL-6
pg/mL
IL-8
pg/mL
IL-10
pg/mL
TNF-a
pg/mL
IFN-g
pg/mL
GM-CSF
pg/mL
IP-10
pg/mL
MIG
pg/mL
MCP-1
pg/mL
Mel. Pt. 1 5/10/2010 5/13/2010 15 11 42 < 14 95 24 < 15 39 12 754
5/10/2010 5/13/2010 10 8 39 < 14 82 22 < 15 40 17 754
5/10/2010 8/11/2010 21 12 44 22 183 20 41 49 32 270
5/10/2010 8/11/2010 24 13 43 29 168 23 51 50 32 268
Mel. Pt. 2 5/10/2010 5/13/2010 18 17 87 < 14 < 10 26 < 15 30 21 1437
5/10/2010 5/13/2010 13 16 95 < 14 < 10 21 < 15 31 17 1494
5/10/2010 8/11/2010 28 30 97 22 10 25 33 38 39 664
5/10/2010 8/11/2010 25 31 86 24 10 24 30 37 28 662
Mel. Pt. 3 5/10/2010 5/13/2010 42 21 72 29 20 < 12 18 190 81 771
5/10/2010 5/13/2010 38 19 70 25 17 < 12 18 188 78 732
5/10/2010 8/11/2010 34 14 73 31 38 9 47 141 96 223
5/10/2010 8/11/2010 36 15 70 28 32 6 50 135 89 198
Mel. Pt. 4 5/10/2010 5/13/2010 68 26 45 51 19 62 107 19 145 955
5/10/2010 5/13/2010 66 24 42 53 18 63 111 18 143 875
5/10/2010 8/11/2010 102 36 26 120 < 10 16 50 19 100 238
5/10/2010 8/11/2010 99 41 24 139 < 10 16 48 20 103 215
Mel. Pt. 5 5/10/2010 5/13/2010 35 64 380 < 14 13 27 78 27 106 831
5/10/2010 5/13/2010 34 61 393 < 14 10 27 82 26 101 737
5/10/2010 8/11/2010 33 43 458 20 16 27 54 32 139 170
5/10/2010 8/11/2010 45 53 480 25 24 34 55 38 146 222
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Page 8 of 14Technologies). Each kit includes reagents to generate an
8-point standard curve from which all values are deter-
mined. For the custom kits we requested, to test a speci-
fic array of analytes of interest, the manufacturer pre-
tests the specific antibodies together, to confirm lack of
cross-reactivity. The manufacturer indicates that the kits
are not released unless the following criteria are met: “
< 10% cross-reactivity to related recombinant protein at
the highest point of the standard curve” (Life Technolo-
gies). We requested the specific cross-reactivity testing
data performed for the kits we used in this study, but
were repeatedly informed that company policy prohibits
QC data release to customers.
As an additional control, we included “Multiplex QC”
controls, which are complex mixtures of recombinant
cytokines, chemokines and growth factors prepared by
the manufacturer at 3 concentrations (low, medium and
high). We have established the reproducibility of this
control (Additional File 4, Table S4) when tested via
Luminex (% CV = 1%-52%, average % CV = 14% for 8
analytes). While the absolute values for each analyte do
not exactly match the “expected” value from the QC
control manufacturer (R&D Systems), they are similar,
and we use a different platform and different antibody
clones for detection via Luminex, which may account
for those differences (as indicated in the package insert).
We also received WHO cytokine standards for IL-4,
IL-8, IL-10 and GM-CSF. These lyophilized cytokine
controls were resuspended (Materials and Methods) and
individually tested at 1:10, 1:50 and 1:100 dilutions in
two replicate Luminex assays for the same ten analytes
described above. These data are presented in Table 4.
As expected, the standard under study was almost
always detected. However, there were some surprising
results. MCP-1 was also almost always detected in addi-
tion to the standard, and MIG was always detected
when the standard IL-10 was used. The apparent con-
centrations of these two analytes in some instances
Figure 2 Time course of analyte concentrations for healthy donors. Assays done on 5/13/2010 and 8/11/2010 were normalized to those
done on 2/02/2010.
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Page 9 of 14exceeded 10% of that of the standard. IL-6, IFN-g and
GM-CSF also showed evidence of minor cross-reactivity.
The apparent cross-reactivity seen for MCP-1 and
MIG might be caused by a medium additive present in
the AIM V medium (a serum-free lymphocyte culture
medium) used in a dilution step for these proteins. We
tested several commonly used culture medias (AIM V,
RPM1640, Iscoves and CellGenix DC media) in a 30-
plex Luminex assay which also included a repeat test of
the WHO standards. The results did identify low levels
(3-62 pg/mL) of several analytes in the culture medias
(HGF, FGF basic, RANTES, IL-17 and IL2R) but not
MCP-1 or MIG (data not shown). The MCP-1 was
again detected in the IL-8 and GM-CSF WHO stan-
dards and MIG in the IL-10 standard (as well as HGF,
FGF basic and RANTES). We are investigating other
possible sources of low levels of other cytokines and
growth factors in the WHO standards.
As a test of the day-to-day reproducibility of two of
the cytokines of particular interest, IL-6 and IL-8, a set
of samples and controls were run in two different cus-
tom kits one day apart (with samples kept thawed, at 4°
C overnight), in which both IL-6 and IL-8 were included
in both kits. Notably, these two kits also had different
standard curves and upper limits of detection. For IL-6,
the 10-plex kit upper limit was 7, 400 pg/mL, while in
the 8-plex, it was 13, 800 pg/mL (1.8 fold higher). For
IL-8, the 10-plex upper limit was 24, 800 pg/mL and in
the 8-plex, 10, 160 pg/mL (2.4 fold lower). When the
values for the 38 samples were compared between the
two kits, the ratio of the IL-6 values was 1.0 (median &
mean), showing excellent concordance. For IL-8, where
t h eu p p e rl i m i t sw e r em o r ed i s p a r a t e ,t h er a t i oo ft h e
values was 0.80, which was a small but significant differ-
ence (Figures 4A and 4B). These data indicate that the
assay with the higher upper limit has larger measured
values.
Upper limit problem
The Luminex kits that we used at the different time
points were not identical. In particular, we noticed that
the upper limits of quantitation for individual analytes
c h a n g e do v e rt i m ef o rt h ed i f f e r e n tk i t s .I np r i n c i p a l ,
this should not affect the measured concentrations,
because the kits include kit-specific standards to gener-
ate 8-point standard curves matched to the expected
Figure 3 Comparison of assay results obtained with sera from healthy donors, new melanoma patients and old melanoma patients.
Points are the ratio of concentrations of the assays done on 8/11/2010 normalized to those done on 5/13/2010.
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Page 10 of 14detection range. However, if the concentration determi-
nations were affected, that would confound our inter-
pretation of the observed changes in analyte
concentration over time, and therefore we investigated
that possibility. Data from assays done on 5/13/2010
("late” assay) were compared to data from assays on 10/
31/2005, 11/1/2005 or 2/17/2006 ("early” assays). Kits
used in 2005 and 2006 had the same upper limits, and
because no samples had assays done on the same date,
results were combined. Figure 5 is a scatter plot of the
late-to-early ratio of analyte concentrations versus the
late-to-early ratio of assay upper limits assays with a
smooth curve is superimposed. The late-to-early ratio of
upper limits was different for each of the 10 analytes.
Typically, 12 samples were assessed for each analyte.
The correlation of the two ratios is highly significant (p
<1 0
-15,S p e a r m a n ’s test). Therefore, we are concerned
that assays performed at different times with different
kits may not be comparable.
In this report, we detail reproducibility problems we
encountered testing circulating cytokines, chemokines
and growth factors by Luminex in serum samples which
were stored over months to years under highly con-
trolled conditions. Some of these changes were very dra-
matic: IL-8 increased 4-6 fold in old patient samples;
MCP-1 decreased 4-6 fold in new patient samples, and
up to 10-fold in healthy donor samples; IL-10 changed
from negative to positive or positive to negative within
t h es a m eo l dp a t i e n ts e r u md a t a s e t( F i g u r e1 ) .O u r
initial hypothesis was that the changes were entirely bio-
logical, and that despite standardized blood handling
procedures and temperature-controlled freezer storage,
some analytes became unstable over time or upon thaw.
Two recent reports testing cytokine stability found most
Table 4 WHO Cytokine Standards
Lab Number Assay
Date
IL-4
pg/mL
IL-6
pg/mL
IL-8
pg/mL
IL-10
pg/mL
TNF-a
pg/mL
IFN-g
pg/mL
GM-CSF
pg/mL
IP-10
pg/mL
MIG
pg/mL
MCP-1
pg/mL
117173 IL-4
1:10 40311 17497 N/A N/A N/A N/A N/A N/A N/A N/A N/A
1:10 40401 11364 N/A N/A N/A N/A N/A N/A N/A N/A 196
1:10 40401 10956 N/A N/A N/A N/A N/A N/A N/A N/A 114
1:50 40311 10945 N/A N/A N/A N/A N/A N/A N/A N/A N/A
1:50 40401 1350 N/A N/A N/A N/A N/A N/A N/A N/A 392
1:50 40401 1321 N/A N/A N/A N/A N/A N/A N/A N/A 1220
117177 IL-8
1:10 40311 N/A N/A 216983 N/A N/A N/A N/A N/A N/A N/A
1:10 40401 N/A N/A 153880 N/A N/A N/A N/A N/A N/A 563
1:10 40401 N/A N/A 153707 N/A N/A N/A N/A N/A N/A 509
1:50 40311 N/A N/A QA N/A N/A N/A N/A N/A N/A N/A
1:50 40401 N/A N/A 45621 N/A N/A N/A N/A N/A N/A 2169
1:50 40401 N/A N/A 46708 N/A N/A N/A N/A N/A N/A 1445
117184 IL-10
1:10 40311 N/A N/A N/A 119338 N/A N/A 180 N/A 1813 N/A
1:10 40401 N/A 230 N/A 72096 N/A N/A N/A N/A 3621 318
1:10 40401 N/A 226 N/A 95800 N/A N/A N/A N/A 3891 389
1:50 40311 N/A N/A N/A 95462 N/A N/A N/A N/A 3836 N/A
1:50 40401 N/A 340 N/A 39419 N/A N/A N/A N/A 4488 1855
1:50 40401 N/A 179 N/A 30223 N/A N/A N/A N/A 4053 1308
117187GM-CSF
1:10 40401 N/A N/A N/A N/A N/A 373 75824 N/A N/A 875
1:10 40401 N/A N/A N/A N/A N/A 272 70453 N/A N/A 721
1:10 40311 N/A N/A N/A N/A N/A N/A 47332 N/A N/A N/A
1:10 40311 N/A N/A N/A N/A N/A N/A 78882 N/A N/A 769
1:50 40311 N/A N/A N/A N/A N/A N/A 59603 N/A N/A N/A
1:50 40311 N/A N/A N/A N/A N/A N/A 76623 N/A N/A 1063
1:50 40311 N/A N/A N/A N/A N/A N/A 19209 N/A N/A 1193
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Page 11 of 14tested cytokines to be stable over 1-2 years at -80°C, and
a subset (including IL-8 and IL-10) became unstable after
2-4 years [24,25]. Many of the proteins became unstable
after repeated freeze-thaw cycles. If these were the only
mechanisms, then the analytes we tested should have
behaved consistently between our three datasets, because
the change would be analyte-specific. This is not the only
explanation, because, for example, MCP-1 increased over
time in the majority of old patient samples and decreased
over time in both HD and new patient sets.
Our study has a number of limitations. The more
recently acquired HD and new patient data sets were
tested within months of blood draw. A better analysis of
the impact of storage time on analyte stability would
require a large number of patients and HD samples
stored for longer periods with costly repeated multiplex
testing. We also limited the diversity of analytes we
examined. Another variable was the time from blood
draw to serum separation and freezing. Some of our
samples were drawn within the laboratory and at our
nearby clinic and processedw i t h i naf e wh o u r s ,w h i l e
other old patient samples were shipped overnight and
processed the following morning. However, the nature
of these blood handling procedures reflects the unavoid-
able limitations inherent in transferring patient blood
from the clinic to a central laboratory capable of stan-
dardized processing, as well as for multi-institutional
trials where large numbers of patients can be treated
and tested, but overnight shipping is required. Lastly,
some of our healthy donor and control samples were
run in duplicate, but to reduce costs, large numbers of
patient sera were run in singlets. Due to the small aver-
age % CVs determined for many duplicates (Additional
File 1, Table S1) this may have minimal impact on the
trends we observed.
Figure 4 Two plates run together compared for A) IL-6 and B) IL-8 values. A set of 38 cell culture samples were run on both an 8-plex and
a 10-plex plate. The values for IL-6 and IL-8 are compared on a log scale. Each plate had a unique upper limit. The values for IL-6 show excellent
concordance, and the 8-plex upper limit was 1.8 times the upper limit. The IL-8 values were reproducibly higher (1.25×) in the 10-plex plate
where the upper limit was 2.4 times higher.
Figure 5 Scatter plot of the late-to-early ratio of analyte
concentrations versus the late-to-early ratio of assay upper
limits of quantitation; a smooth curve is superimposed. Early
assays were done on 10/31/2005, 11/01/2005 or 2/17/2006; late
assays were done on 5/13/2010.
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Page 12 of 14The Luminex assay has been shown (by ourselves [26]
and others [27]) to show good correspondence to ELISA
platform assays. In addition, the Luminex assay has
good reproducibility from well-to-well, and from day-to-
day (Figure 4). Also, our use of the R&D QC controls
(Additional File 4, Table S4) indicate good reproducibil-
ity of recombinant analytes when mixed together. This
may indicate that the serum matrix may impact repro-
ducibility, and/or the biological impact of a tumor may
lead to systemic changes (including altered glycosyla-
tion) which impact the assay.
This study also suggests that the changes in the upper
limits of detection, which can vary substantially from kit
to kit, month to month, and analyte to analyte from a
single manufacturer, may impact the ability to deter-
mine analyte concentration. This impacts kit-to-kit
reproducibility, and greatly increases the importance of
comparing samples with the identical lot of kits with
identical standard curve ranges. We attempted to dissect
this further by requesting access to manufacturer QC
data, but we were repeatedly denied access to any addi-
tional information specific to the testing performed on
the kits we used.
We do not understand why the assay kit upper limits
seem to affect assay performance in the systematic way
that is evident in Figure 5. However, we have to con-
clude that the results of assays done with different kits
cannot be directly compared. Therefore, the apparent
changes in analyte levels over time that we observe may
arise from the kit-to-kit variability: we cannot claim to
observe changes in analyte levels over storage time at
-80°C.
Conclusions
In conclusion, the multiplex Luminex platform offers
the opportunity to test a wide variety of analytes in the
same sample, with minimal volume requirements, and
good well-to-well and day-to-day reproducibility. These
attributes are important when broadly searching for
serum biomarkers. However, we find that a number of
commonly tested candidate immunologic biomarkers
show evidence of unexpected, large variability when
tested retrospectively, after long storage times. This
variability can be reduced by 1) performing assays with
kits from a single lot, and potentially 2) minimizing sto-
rage time before retrospective analysis of banked serum.
Additional material
Additional file 1: Table S1: Luminex kit details. This table includes
upper and lower limits of detection and %CVs.
Additional file 2: Table S2: Healthy Donor Demographics. This table
includes age, race and gender information.
Additional file 3: Table S3: New Melanoma Patient Demographics.
This table includes age, race, gender and treatment information.
Additional file 4: Table S4: R&D Systems QC Control Data. This table
includes control sample values and %CVs.
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